Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
Carroccio, A., DI PRIMA, L., Pirrone, G., Ambrosiano, G., Noto, D., Cefal, A. (2006). Terapia biologica con infliximab (anti-TNF) nella malattia di Crohn: analisi delle complicanze. RECENTI PROGRESSI IN MEDICINA, 97(2), 108-112.
Terapia biologica con infliximab (anti-TNF) nella malattia di Crohn: analisi delle complicanze.
CARROCCIO, Antonio;DI PRIMA, Lidia;AMBROSIANO, Giuseppe;NOTO D;CEFALU', Angelo Baldassare
2006-01-01
Abstract
Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
